<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888302</url>
  </required_header>
  <id_info>
    <org_study_id>MC1243</org_study_id>
    <secondary_id>NCI-2013-01183</secondary_id>
    <secondary_id>12-007515</secondary_id>
    <secondary_id>MC1243</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT01888302</nct_id>
  </id_info>
  <brief_title>Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery</brief_title>
  <official_title>Pilot Trial of Sirolimus, Gemcitabine and Cisplatin for Patients With High Risk for Cholangiocarcinoma Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I trial studies the side effects and best way to give sirolimus, gemcitabine&#xD;
      hydrochloride, and cisplatin in treating patients at high risk for cholangiocarcinoma&#xD;
      recurrence after liver transplant or surgery. Sirolimus may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as&#xD;
      gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving sirolimus with&#xD;
      gemcitabine hydrochloride and cisplatin may prevent disease recurrence in patients with a&#xD;
      high risk of recurrence after a liver transplant or surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assessment of the percentage of patients who are able to complete therapy through 4 and 6&#xD;
      months post-registration.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the adverse events, rate of dose reductions, and quality of life in these&#xD;
      patients.&#xD;
&#xD;
      II. To summarize timed endpoints of time-to-recurrence, disease-free survival, overall&#xD;
      survival, time to treatment failure, and time until treatment related grade 3+ adverse&#xD;
      events.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive cisplatin intravenously (IV) over 1 hour and gemcitabine hydrochloride IV&#xD;
      over 30 minutes on days 1 and 8, and sirolimus orally (PO) daily or three times weekly.&#xD;
      Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months for up to 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who are able to complete therapy</measure>
    <time_frame>Up to 6 months post-registration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hepatic Complication</condition>
  <arm_group>
    <arm_group_label>Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)</arm_group_label>
    <other_name>AY 22989</other_name>
    <other_name>RAPA</other_name>
    <other_name>Rapamune</other_name>
    <other_name>RAPAMYCIN</other_name>
    <other_name>SILA 9268A</other_name>
    <other_name>WY-090217</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic proof of presence of residual tumor in liver explants and /or positive&#xD;
             resection margins&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/μL obtained =&lt; 7 days prior to registration&#xD;
&#xD;
          -  Platelets (PLT) &gt;= 100,000/μL obtained =&lt; 7 days prior to registration&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN) obtained =&lt; 7 days&#xD;
             prior to registration&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x ULN&#xD;
             obtained =&lt; 7 days prior to registration (=&lt; 5 x ULN in patients with liver&#xD;
             metastases)&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x Institutional ULN obtained =&lt; 7 days prior to registration&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 5 x institutional ULN obtained =&lt; 7 days prior to registration&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 9.0 g/dL obtained =&lt; 7 days prior to registration&#xD;
&#xD;
          -  International normalized ratio (INR) and partial thromboplastin (PTT) =&lt; 3.0 x ULN&#xD;
             (anticoagulation is allowed if target INR =&lt; 3.0 x ULN on a stable dose of warfarin or&#xD;
             on a stable dose of low molecular weight [LMW] heparin for &gt; 2 weeks at time of&#xD;
             registration)&#xD;
&#xD;
          -  Fasting serum glucose &lt; 1.5 x ULN obtained =&lt; 7 days prior to registration&#xD;
&#xD;
          -  Fasting serum cholesterol =&lt; 300 mg/dL OR =&lt; 7.75 mmol/L AND fasting triglycerides =&lt;&#xD;
             2.5 x ULN obtained =&lt; 90 days prior to registration; NOTE: In case one or both of&#xD;
             these thresholds are exceeded, the patient can only be included after initiation of&#xD;
             appropriate lipid lowering medication&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Willingness to return to Mayo Clinic for follow up&#xD;
&#xD;
          -  Life expectancy &gt;= 12 months&#xD;
&#xD;
          -  Women of childbearing potential only: negative serum pregnancy test done =&lt; 7 days&#xD;
             prior to registration&#xD;
&#xD;
          -  Four months post liver transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Clinically significant cardiac disease, especially history of myocardial infarction =&lt;&#xD;
             6 months, or congestive heart failure (New York Heart Association [NYHA]&#xD;
             classification III or IV) requiring use of ongoing maintenance therapy for&#xD;
             life-threatening ventricular arrhythmias&#xD;
&#xD;
          -  Taking strong inhibitors or strong/moderate inducers of cytochrome P450 (CYP)3A4&#xD;
&#xD;
               -  Strong inhibitors of CYP3A4/5; &gt; 5-fold increase in the plasma area under the&#xD;
                  curve (AUC) values or more than 80% decrease in clearance&#xD;
&#xD;
                    -  Clarithromycin (Biaxin®, Biaxin XL®)&#xD;
&#xD;
                    -  Conivaptan (Vaprisol®)&#xD;
&#xD;
                    -  Grapefruit juice&#xD;
&#xD;
                    -  Itraconazole (Sporanox®)&#xD;
&#xD;
                    -  Ketoconazole (Nizoral®)&#xD;
&#xD;
                    -  Mibefradil&#xD;
&#xD;
                    -  Nefazodone (Serzone®)&#xD;
&#xD;
                    -  Posaconazole (Noxafil®)&#xD;
&#xD;
                    -  Telaprevir (Incivek®)&#xD;
&#xD;
                    -  Telithromycin (Ketek®)&#xD;
&#xD;
               -  Use of the following inducers are prohibited =&lt; 7 days prior to registration&#xD;
&#xD;
                    -  Strong inducers of CYP3A4/5; &gt; 80% decrease in AUC&#xD;
&#xD;
                         -  Avasimibe&#xD;
&#xD;
                         -  Carbamazepine (Carbatrol®, Epitol®, Equetro™, Tegretol®, Tegretol-XR®)&#xD;
&#xD;
                         -  Phenytoin (Dilantin®, Phenytek®)&#xD;
&#xD;
                         -  Rifampin (Rifadin®)&#xD;
&#xD;
                         -  St. John's wort&#xD;
&#xD;
                    -  Moderate inducers of CYP3A4/5; 50-80% decrease in AUC&#xD;
&#xD;
                         -  Bosentan (Tracleer®)&#xD;
&#xD;
                         -  Modafinil (Provigil®)&#xD;
&#xD;
                         -  Nafcillin&#xD;
&#xD;
                         -  Phenobarbital (Luminal®)&#xD;
&#xD;
                         -  Rifabutin (Mycobutin®)&#xD;
&#xD;
                         -  Troglitazone&#xD;
&#xD;
          -  Any of the following prior therapies:&#xD;
&#xD;
               -  Chemotherapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Mitomycin C/nitrosoureas =&lt; 6 weeks prior to registration&#xD;
&#xD;
               -  Immunotherapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Biologic therapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Radiation therapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Radiation to &gt; 25% of bone marrow prior to registration&#xD;
&#xD;
          -  Failure to fully recover from acute, reversible effects of prior surgery or&#xD;
             chemotherapy regardless of interval since last treatment&#xD;
&#xD;
          -  Any of the following because this study involves cytotoxic agents&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy&#xD;
             considered investigational (utilized for a non-Food and Drug Administration&#xD;
             [FDA]-approved indication and in the context of a research investigation)&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens&#xD;
&#xD;
          -  Immunocompromised patients (other than that related to the use of corticosteroids)&#xD;
             including patients known to be human immunodeficiency virus (HIV) positive with low&#xD;
             cluster of differentiation (CD)4 count; Note: previous calcineurin inhibitor or&#xD;
             previous sirolimus use allowed&#xD;
&#xD;
          -  Current active other malignancy, except non-melanoma skin cancer or carcinoma-in-situ&#xD;
             of the cervix; if there is a history of prior malignancy, they must not be receiving&#xD;
             other specific treatment (other than hormonal therapy) for their cancer&#xD;
&#xD;
          -  Current impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of sirolimus (e.g., active ulcerative disease,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel&#xD;
             resection)&#xD;
&#xD;
          -  Current severely impaired lung function (i.e., forced expiratory volume in 1 second&#xD;
             [FEV1] &lt; 1 liter)&#xD;
&#xD;
          -  Received immunization with attenuated live vaccines =&lt; 7 days prior to study entry or&#xD;
             during study period; NOTE: Close contact with those who have received attenuated live&#xD;
             vaccines should be avoided during treatment with sirolimus; examples of live vaccines&#xD;
             include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus&#xD;
             Calmette-Guérin (BCG), yellow fever, varicella and typhoid (TY)21a typhoid vaccines&#xD;
&#xD;
          -  Current severe hepatic impairment; Note: A detailed assessment of hepatitis B/C&#xD;
             medical history and risk factors must be done at screening for all patients; hepatitis&#xD;
             B virus (HBV) deoxyribonucleic acid (DNA) and hepatitis C virus (HCV) ribonucleic acid&#xD;
             (RNA) polymerase chain reaction (PCR) testing are required at screening for all&#xD;
             patients with a positive medical history based on risk factors and/or confirmation of&#xD;
             prior HBV/HCV infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Alberts</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

